Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma.
Cytokines
Inflammation
Melanoma
Neutrophils
Paraneoplastic leukemoid reaction
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
20
04
2021
accepted:
24
06
2022
pubmed:
17
7
2022
medline:
26
1
2023
entrez:
16
7
2022
Statut:
ppublish
Résumé
Paraneoplastic leukemoid reaction (PLR) is a rare phenomenon in metastasized melanoma associated with poor prognosis and rapid disease progression. Currently, no specific therapeutic options exist other than treating the underlying malignancy. Five cases of paraneoplastic neutrophilia in patients with advanced-stage IV melanoma were enrolled in our study. Cytokine concentrations in patients' serum samples were analyzed before and during PLR using a multiplex cytokine array. Further, immunohistochemical staining of tumor tissue biopsied during PLR was performed. We observed a strong correlation between worsening of tumor burden and aggravation of neutrophilia. Cytokine measurements revealed an increase of proinflammatory cytokines (IL6, IFNγ), proangiogenic cytokines (VEGF) and immune stem cell growth factors (G-CSF) during PLR. Immunohistochemistry confirmed neutrophil infiltration of tumor tissue. The presented cytokine alterations provide a basis for further functional analysis, which is necessary for the development of targeted therapeutic approaches against PLR.
Sections du résumé
BACKGROUND
BACKGROUND
Paraneoplastic leukemoid reaction (PLR) is a rare phenomenon in metastasized melanoma associated with poor prognosis and rapid disease progression. Currently, no specific therapeutic options exist other than treating the underlying malignancy.
METHODS
METHODS
Five cases of paraneoplastic neutrophilia in patients with advanced-stage IV melanoma were enrolled in our study. Cytokine concentrations in patients' serum samples were analyzed before and during PLR using a multiplex cytokine array. Further, immunohistochemical staining of tumor tissue biopsied during PLR was performed.
RESULTS AND CONCLUSIONS
CONCLUSIONS
We observed a strong correlation between worsening of tumor burden and aggravation of neutrophilia. Cytokine measurements revealed an increase of proinflammatory cytokines (IL6, IFNγ), proangiogenic cytokines (VEGF) and immune stem cell growth factors (G-CSF) during PLR. Immunohistochemistry confirmed neutrophil infiltration of tumor tissue. The presented cytokine alterations provide a basis for further functional analysis, which is necessary for the development of targeted therapeutic approaches against PLR.
Identifiants
pubmed: 35841421
doi: 10.1007/s00262-022-03249-7
pii: 10.1007/s00262-022-03249-7
pmc: PMC9870824
doi:
Substances chimiques
Cytokines
0
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
509-513Informations de copyright
© 2022. The Author(s).
Références
Gouveia E, Sousa M, Passos MJ, Moreira A (2015) Paraneoplastic leukemoid reaction in a patient with BRAF V600E-mutated metastatic malignant melanoma. BMJ Case Rep. https://doi.org/10.1136/bcr-2014-208645
doi: 10.1136/bcr-2014-208645
McCoach CE, Rogers JG, Dwyre DM, Jonas BA (2015) Paraneoplastic leukemoid reaction as a marker of tumor progression in non-small cell lung cancer. Cancer Treat Commun 4:15–18. https://doi.org/10.1016/j.ctrc.2015.03.003
doi: 10.1016/j.ctrc.2015.03.003
Abukhiran IA, Jasser J, Syrbu S (2020) Paraneoplastic leukemoid reactions induced by cytokine-secreting tumours. J Clin Pathol 73:310–313. https://doi.org/10.1136/jclinpath-2019-206340
doi: 10.1136/jclinpath-2019-206340
Davis JL, Ripley RT, Frankel TL et al (2010) Paraneoplastic granulocytosis in metastatic melanoma. Melanoma Res 20:326–329. https://doi.org/10.1097/CMR.0b013e328339da1e
doi: 10.1097/CMR.0b013e328339da1e
Schniewind B, Christgen M, Hauschild A et al (2005) Paraneoplastic leukemoid reaction and rapid progression in a patient with malignant melanoma: establishment of KT293, a novel G-CSF-secreting melanoma cell line. Cancer Biol Ther 4:23–27. https://doi.org/10.4161/cbt.4.1.1447
doi: 10.4161/cbt.4.1.1447
Åström M, Tajeddinn W, Karlsson MG et al (2018) Cytokine measurements for diagnosing and characterizing leukemoid reactions and immunohistochemical validation of a granulocyte colony-stimulating factor and CXCL8-producing renal cell carcinoma. Biomark Insights. https://doi.org/10.1177/1177271918792246
doi: 10.1177/1177271918792246
Zaidi MR, Merlino G (2011) The two faces of interferon-γ in cancer. Clin Cancer Res 17:6118–6124. https://doi.org/10.1158/1078-0432.CCR-11-0482
doi: 10.1158/1078-0432.CCR-11-0482
Laino AS, Woods D, Vassallo M et al (2020) Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer 8:e000842. https://doi.org/10.1136/jitc-2020-000842
doi: 10.1136/jitc-2020-000842
Grivennikov S, Karin E, Terzic J et al (2009) IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis associated cancer. Cancer Cell 15:103–113. https://doi.org/10.1016/j.ccr.2009.01.001
doi: 10.1016/j.ccr.2009.01.001
Ahmed A, Köhler S, Klotz R et al (2021) Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic ductal adenocarcinoma. OncoImmunology 10:1962135. https://doi.org/10.1080/2162402X.2021.1962135
doi: 10.1080/2162402X.2021.1962135
Jones SA, Jenkins BJ (2018) Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 18:773–789. https://doi.org/10.1038/s41577-018-0066-7
doi: 10.1038/s41577-018-0066-7
Teachey DT, Rheingold SR, Maude SL et al (2013) Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121:5154–5157. https://doi.org/10.1182/blood-2013-02-485623
doi: 10.1182/blood-2013-02-485623